![Longitudinal changes in depression (measured by the Participant Health Questionnaire-9 [PHQ-9]), anxiety (Hospital and Anxiety Depression Scale [HADS]), and posttraumatic stress disorder (PTSD; measured by the 6-item PTSD Checklist [PCL-6]) following psilocybin services (baseline, 346 participants; 1 month, 321 participants; 3 months, 312 participants). Orange band indicates 95% CIs; horizontal blue line, delineation between moderate-to-severe symptoms and none-to-mild symptoms.](https://pbs.twimg.com/media/HQfBYZUXcAANCF7.jpg?name=small&format=webp)
ALT Longitudinal changes in depression (measured by the Participant Health Questionnaire-9 [PHQ-9]), anxiety (Hospital and Anxiety Depression Scale [HADS]), and posttraumatic stress disorder (PTSD; measured by the 6-item PTSD Checklist [PCL-6]) following psilocybin services (baseline, 346 participants; 1 month, 321 participants; 3 months, 312 participants). Orange band indicates 95% CIs; horizontal blue line, delineation between moderate-to-severe symptoms and none-to-mild symptoms.

ALT Early detection of infectious avatars by the PPS system. a, VR setup. Participants were first exposed to a neutral avatar (baseline) and then assigned to one of three cohorts encountering neutral, infectious or fearful avatars in a second session. b, PPS task. Participants responded to tactile stimuli on their face, delivered either in empty space (unisensory) or combined with an avatar approaching (multisensory). Tactile stimuli (flash icon) were presented at five delays, with the avatar located at one of five distances (D5 = far, D1 = near). c, PPS representation across cohorts. Reaction times (RTs) to multisensory stimuli were normalized by unisensory RTs (dotted line) and plotted by avatar distance. Shaded areas illustrate the PPS gradient, defined by significantly faster multisensory RTs (P < 0.05, corrected; paired-sample t-tests); N = 15 per cohort. Data are shown as mean ± s.e.m. (see Supplementary Table 3 for full statistics).

















